SEC Comment Letter 0000000000-25-001989 to Telomir Pharmaceuticals, Inc. (TELO) (CIK 0001971532) (TELO)
Telomir Pharmaceuticals, Inc. (TELO) (CIK 0001971532)
Date: Feb. 20, 2025 · CIK: 0001971532 · Accession: 0000000000-25-001989
AI Filing Summary & Sentiment
File numbers found in text: 333-284990
Letter
February 20, 2025 Erez Aminov Chief Executive Officer Telomir Pharmaceuticals, Inc. 100 SE 2nd St, Suite 2000, #1009 Miami, Florida 33131 Re:Telomir Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed February 14, 2025 File No. 333-284990 Dear Erez Aminov: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Max Lindenfeld, Esq.
Show Raw Text
February 20, 2025
Erez Aminov
Chief Executive Officer
Telomir Pharmaceuticals, Inc.
100 SE 2nd St, Suite 2000, #1009
Miami, Florida 33131
Re:Telomir Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed February 14, 2025
File No. 333-284990
Dear Erez Aminov:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Max Lindenfeld, Esq.